Harness their
natural strength^1,2

Consider ECP to modulate their
dysregulated immune system and support
them beyond just symptom control^3-6
^THERAKOS ECP Immunomodulation™ employs the patient's own immune cells to modulate disregulated immune function^1-5,7-10.
The exact mechanism of action (MOA) of the photosensitising agent is unknown. Individual results may vary.

Important Safety Information

What do you get when you choose THERAKOS ECP Immunomodulation™?

ECP Strength

Evidence-based Treatment^11-19
Immunomodulation^3-5
Cost-effectiveness^21-24

THERAKOS ECP EDGE

CELLEX™ System Performance^25,26
Validated Technology^11,26,27
Patient & Customer Focus
Access & Delivery Support
The Therakos Institute

A close-up of a part of a cell in the bottom left corner with a visible part of nucleus

Therakos ECP Immunomodulation™

Find out more about our therapy and its clinical applications

Discover More

THERAKOS™ CELLEX™ Photopheresis System

Learn about the world’s only fully integrated and validated ECP system

Discover More

Research Opportunities & Educational Grants

Discover educational grants and research opportunities available to you

DISCOVER MORE

Health Economics

Learn about the potential economic benefits of choosing CELLEX^TM, and find out about our funding support services

DISCOVER MORE

Healthcare professional with a blurred-out medical device

Customer Support

Get in touch with us

DISCOVER MORE

References
1. Operator’s Manual. THERAKOS^TM CELLEX^TM Photopheresis System. Therakos. 2019. 2. Hart JW, et al. Ther Adv Hematol. 2013;4:320-334. 3. Wang L, et al. Front Immunol. 2018;9:2207. 4. Ni M, et al. Front Immunol. 2019;10:547. 5. Mankarious M, et al. Front Immunol. 2020;11:81. 6. Dignan FL, et al. Bone Marrow Transplant. 2014;49(5):704-708. 7. Yoo EK, et al. J Invest Dermatol. 1996;107:235-242. 8. Morelli AE, et al. Blood. 2003;101:611-620. 9. Craciun LI, et al. Transplantation. 2002;74:995-1000. 10. Lamioni A, et al. Transplantation. 2005;79:846-850. 11. Knobler R, et al. J Eur Acad Dermatol Venereol. 2020;34(12):2693-2716. 12. Cho A, et al. Front Med (Lausanne). 2018;5:236. 13. Trautinger F, et al. Eur J Cancer. 2017;77:57-74. 14. Padmanabhan A, et al. J Clin Apher. 2019;34(3):171- 354. 15. Alfred A, et al. Br J Haematol. 2017;177:287-310. 16. Dignan FL, et al. Br J Haematol. 2012;158(1):30–45. 17. Pierelli L, et al. Transfusion. 2013;53(10):2340-2352. 18. Zeiser R. et al. Graft-versus-Host Erkrankung, akut. 2021. Available at: https://www.onkopedia.com/de/onkopedia/guidelines/graft-versus-host-erkrankung-akut/@@view/html/index.html. Accessed February 2022. 19. Costanzo MR, et al. J Heart Lung Transplant. 2010;29(8):914-956 20. Crespo C, et al. Clin Ther. 2012;34(8):1774-1787. 21. Walczak J, et al. Value Health. 2012;15:A349. 22. de Waure C, et al. Value Health. 2015;18(4):457-466. 23. Geskin L, Malone DC. J Dermatolog Treat. 2018;29(5):522-530. 24. Mayer W, et al. Retrospective data analysis related to the use of open and closed extracorporeal photopheresis systems. Presented at the 40th annual meeting of the American Society for Apheresis; 14-18 May, 2019, Portland, USA. Available at: https://doi.org/10.1002/jca.21704. Accessed November 2021. 25. Linic B, et al. The implementation of ‘lean’ working practices and THERAKOS^TM CELLEX^TM have resulted in a 50% increase in patient treatments with the same number of nurses employed in the unit. Presented at the 20th congress of the European Hematology Association; 11-14 June, 2015, Vienna, Austria. Poster E1428. 26. Therakos (UK) Ltd. Data on file - ref-06130. 27. Therakos (UK) Ltd. Data on file - ref-04301.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Harness theirnatural strength1,2